{"schema_version":"secwatch.filing_event.v1","accession":"0001689375-24-000045","form_type":"8-K","ticker":"TRDA","cik":"0001689375","company_name":"Entrada Therapeutics, Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.117640+00:00","generated_at":"2026-05-31T09:44:50.557133+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Entrada Q2 net income $55M, positive Phase 1 data for DMD candidate ENTR-601-44","bullets":["Q2 net income of $55.0M vs net loss of $25.9M YoY; collaboration revenue $94.7M (up from $18.2M).","Completed $100M registered direct offering; cash & securities $469.7M as of June 30, 2024; runway into 2027.","Phase 1 trial of ENTR-601-44 showed dose-dependent plasma/muscle concentration and exon skipping; no serious adverse events.","Planning global Phase 2 trials for ENTR-601-44 and ENTR-601-45; regulatory filings expected Q4 2024; ENTR-601-50 filing planned 2025.","Vertex VX-670 DM1 trial enrolling; SAD portion expected to complete by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001689375-24-000045","json":"https://secwatch.observer/filing/0001689375-24-000045.json","markdown":"https://secwatch.observer/filing/0001689375-24-000045.md","text":"https://secwatch.observer/filing/0001689375-24-000045.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000045/0001689375-24-000045-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1689375/000168937524000045/trda-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:50.557133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}